Whereas growth in EGFR-expressing mesothelioma cell lines is significantly deterred by EGFR small molecule inhibitors [45], clinical evaluations of gefitinib and erlotinib were dismal in MPM patients [46,47]. Here, EGFR is linked to mesothelioma.